In this presentation, Shannon R. McCurdy, MD, offers a discerning overview of recent updates in the treatment of acute leukemia for the year 2017, a “remarkable year” that saw 17 FDA approvals for the hematological malignancies, including ALL, AML, follicular lymphoma, multiple myeloma and CLL, primarily among immunotherapies. Dr. McCurdy then provides a profile of each of these agents in turn as presented at ASH 2017.
Enrolling Clinical Trials: Combination Chemotherapy / Immunotherapy for Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Dr McCurdy’s Penn Profile
Connect on Doximity